BIA
ALNY icon

Bell Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bell Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8K Sell
49
-4
-8% -$1.21K ﹤0.01% 577
2026
Q1 		$17.5K Buy
53
+17
+47% +$5.79K ﹤0.01% 480
2025
Q4 		$14.3K Hold
36
– – ﹤0.01% 565
2025
Q3 		$16.4K Buy
36
+1
+3% +$407 ﹤0.01% 471
2025
Q2 		$11.4K Sell
35
-2
-5% -$553 ﹤0.01% 623
2025
Q1 		$9.99K Buy
37
+6
+19% +$1.54K ﹤0.01% 603
2024
Q4 		$7.29K Sell
31
-6
-16% -$1.58K ﹤0.01% 741
2024
Q3 		$10.2K Buy
37
+2
+6% +$521 ﹤0.01% 614
2024
Q2 		$8.51K Sell
35
-1
-3% -$158 ﹤0.01% 676
2024
Q1 		$5.38K Buy
36
+3
+9% +$500 ﹤0.01% 873
2023
Q4 		$6.32K Sell
33
-5
-13% -$852 ﹤0.01% 753
2023
Q3 		$6.73K Hold
38
– – ﹤0.01% 665
2023
Q2 		$7.22K Hold
38
– – ﹤0.01% 635
2023
Q1 		$7.61K Sell
38
-7
-16% -$1.47K ﹤0.01% 582
2022
Q4 		$10.7K Sell
45
-1
-2% -$213 ﹤0.01% 468
2022
Q3 		$9K Buy
46
+16
+53% +$3.05K ﹤0.01% 435
2022
Q2 		$4K Buy
+30
New +$4.26K ﹤0.01% 763
2021
Q4 		$3K Sell
18
-4
-18% -$743 ﹤0.01% 938
2021
Q3 		$4K Buy
+22
New +$4.13K ﹤0.01% 764

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's ALNY Position: Q2 2026 in Review

Bell Investment Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 7.5% in Q2 2026, selling an estimated $1.21K and leaving 49 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #577.

Bell Investment Advisors first reported a position in ALNY in Q3 2021 and has held it in 19 quarters since. The position peaked at $17.5K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bell Investment Advisors held 49 shares of Alnylam Pharmaceuticals worth $14.8K as of Q2 2026.
  • Bell Investment Advisors sold 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #577 holding.
  • Bell Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Bell Investment Advisors's Alnylam Pharmaceuticals position peaked at $17.5K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.